| Literature DB >> 26818050 |
Marta Scorsetti1, Francesco Leo2, Annalisa Trama3, Rolando D'Angelillo4, Danila Serpico3, Marianna Macerelli5, Paolo Zucali6, Gemma Gatta3, Marina Chiara Garassino7.
Abstract
Thymomas (Ts) and thymic carcinomas (TCs) are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe. Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes (A, AB, B1, B2, B3, and C), while staging system concerns localisation of the involved areas. Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection. Radiotherapy has a role in selected cases (stage III patients or R1-2 residual) and platinum-based chemotherapy remains the standard of care for patients with advanced disease. A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied. In this review, we describe key aspects of clinical management for Ts and TCs.Entities:
Keywords: Chemotherapy; Diagnosis; Radiotherapy; Surgery; Targeted therapies; Thymic carcinoma; Thymomas
Mesh：
Year: 2016 PMID： 26818050 DOI： 10.1016/j.critrevonc.2016.01.012
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312